COVID-19 Vaccine: Where Do We Stand Now?
COVID-19: The biggest challenge with the pandemic lies in not only developing a successful vaccine but also producing it in quantities necessary to provide immunity to all citizens. Competition is already emerging over who will have access once a vaccine is ready.
COVID-19: The biggest challenge with the pandemic lies in not only developing a successful vaccine but also producing it in quantities necessary to provide immunity to all citizens. Competition is already emerging over who will have access once a vaccine is ready.
‘UK's most vulnerable could get the COVID-19 vaccine by Christmas.’
Tweet it Now
While she was optimistic that the COVID-19 vaccine would be found, it was "very unlikely" to be a single jab, suggesting that revaccination probably every few years might be needed, reported the BBC. If the virus that causes COVID-19 mutates significantly, the vaccine's effort might have to start from scratch again.
The UK government and the Joint Committee on Vaccination and Immunization (JCVI) would agree on who should get the vaccine and when.
Johnson & Johnson Stops COVID-19 Vaccine Trial Temporarily
US pharmaceutical giant Johnson & Johnson announced that it has temporarily paused its COVID-19 vaccine trial after a participant became unwell.
US pharmaceutical giant Johnson & Johnson announced that it has temporarily paused its COVID-19 vaccine trial after a participant became unwell.
Around the world, hundreds of trials are being conducted to find an effective coronavirus vaccine, including six candidates being developed in Britain.
Advertisement
COVID-19 Vaccine Likely by Early 2021
The COVID-19 vaccine would most likely be ready by the first quarter of 2021. The government is planning first to vaccinate senior citizens and high-risk people.
The COVID-19 vaccine would most likely be ready by the first quarter of 2021. The government is planning first to vaccinate senior citizens and high-risk people.
COVID-19 Vaccine COVAXIN's Animal Trial Gets Robust Immune Responses
In animal studies, the COVID-19 vaccine candidate, COVAXIN has shown positive efficacy and generated robust immune responses, said Bharat Biotech International Limited.
In animal studies, the COVID-19 vaccine candidate, COVAXIN has shown positive efficacy and generated robust immune responses, said Bharat Biotech International Limited.
